Department of Neurosurgery, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Department of Physiology and Pharmacology, School of Medicine, Loma Linda University, Loma Linda, CA, United States.
Front Immunol. 2020 Feb 26;11:294. doi: 10.3389/fimmu.2020.00294. eCollection 2020.
Ischemic stroke, which accounts for 75-80% of all strokes, is the predominant cause of morbidity and mortality worldwide. The post-stroke immune response has recently emerged as a new breakthrough target in the treatment strategy for ischemic stroke. Glial cells, including microglia, astrocytes, and oligodendrocytes, are the primary components of the peri-infarct environment in the central nervous system (CNS) and have been implicated in post-stroke immune regulation. However, increasing evidence suggests that glial cells exert beneficial and detrimental effects during ischemic stroke. Microglia, which survey CNS homeostasis and regulate innate immune responses, are rapidly activated after ischemic stroke. Activated microglia release inflammatory cytokines that induce neuronal tissue injury. By contrast, anti-inflammatory cytokines and neurotrophic factors secreted by alternatively activated microglia are beneficial for recovery after ischemic stroke. Astrocyte activation and reactive gliosis in ischemic stroke contribute to limiting brain injury and re-establishing CNS homeostasis. However, glial scarring hinders neuronal reconnection and extension. Neuroinflammation affects the demyelination and remyelination of oligodendrocytes. Myelin-associated antigens released from oligodendrocytes activate peripheral T cells, thereby resulting in the autoimmune response. Oligodendrocyte precursor cells, which can differentiate into oligodendrocytes, follow an ischemic stroke and may result in functional recovery. Herein, we discuss the mechanisms of post-stroke immune regulation mediated by glial cells and the interaction between glial cells and neurons. In addition, we describe the potential roles of various glial cells at different stages of ischemic stroke and discuss future intervention targets.
缺血性脑卒中占所有脑卒中的 75-80%,是全球发病率和死亡率的主要原因。卒中后免疫反应最近成为缺血性卒中治疗策略的一个新的突破靶点。神经胶质细胞,包括小胶质细胞、星形胶质细胞和少突胶质细胞,是中枢神经系统(CNS)梗死周围环境的主要组成部分,并与卒中后免疫调节有关。然而,越来越多的证据表明,胶质细胞在缺血性卒中期间发挥有益和有害的作用。小胶质细胞监测中枢神经系统的内稳态并调节先天免疫反应,在缺血性卒中后迅速被激活。激活的小胶质细胞释放炎症细胞因子,诱导神经元组织损伤。相比之下,在缺血性卒中后被激活的小胶质细胞分泌抗炎细胞因子和神经营养因子,对恢复是有益的。星形胶质细胞的激活和缺血性卒中时的反应性神经胶质增生有助于限制脑损伤和重建中枢神经系统的内稳态。然而,神经胶质瘢痕阻碍了神经元的重新连接和延伸。神经炎症影响少突胶质细胞的脱髓鞘和再髓鞘化。少突胶质细胞释放的髓鞘相关抗原激活外周 T 细胞,从而导致自身免疫反应。少突胶质前体细胞可以分化为少突胶质细胞,在缺血性卒中后被激活,并可能导致功能恢复。在此,我们讨论了由胶质细胞介导的卒中后免疫调节机制以及胶质细胞与神经元之间的相互作用。此外,我们描述了各种胶质细胞在缺血性卒中不同阶段的潜在作用,并讨论了未来的干预靶点。